Announcing ClickHouse Cloud: Democratizing lightning-fast insights and analytics
4.10.2022 17:00:00 EEST | Business Wire | Press release
Today, ClickHouse, Inc. announced the launch of ClickHouse Cloud, a lightning-fast cloud-based database that simplifies and accelerates insights and analytics for modern digital enterprises. With no infrastructure to manage, ClickHouse Cloud architecture decouples storage and compute and scales automatically to accommodate modern workloads, so users do not have to size and tune their clusters to achieve blazing-fast query speeds.
Historically, data infrastructure and analytics solutions have been expensive and difficult to manage. Companies frequently bore the expense of specialized experts and infrastructure teams, only to receive unacceptable performance in return, as legacy solutions struggled to scale. The introduction of ClickHouse Cloud, built by the creators of the much-loved open source project, brings enterprise-grade data analytics and lightning-fast insights to the masses. A ClickHouse Cloud user can log in and launch a new service with a few clicks, and start analyzing their own data in under five minutes.
ClickHouse Cloud, initially released in Beta on AWS, and coming soon on other cloud providers, is highly available and secure by default, so users can focus on developing business-critical applications without the overhead of tuning cluster topology settings. Developers can adopt the latest ClickHouse capabilities, and never have to worry about time-consuming manual upgrades. Built on strong security and privacy fundamentals, the service is already SOC 2 Type I and GDPR compliant, with additional certifications in progress.
ClickHouse Cloud is fully self-service, with a simple, transparent pricing model that allows users to pay only for the resources they use without the need to over-provision for peak workloads. Existing ClickHouse users can migrate to ClickHouse Cloud with just a few simple steps, and new users can get started just as easily. ClickHouse Cloud features a robust partner integration ecosystem for data onboarding, data visualization, and language clients, further accelerating developer and analyst productivity.
“ClickHouse was built to enable our users to derive insights in real time from ever-increasing data volumes. Now the experience our open source users have loved for years is available in a simple and easy-to-use cloud service. It takes just a few minutes to get started, and the rich and growing ecosystem of integrations and partners makes it even easier to ingest and analyze data. We believe this intersection of incredibly high speed and amazingly efficient scale delivers critical advantages to our customers,” says Aaron Katz, co-founder and CEO of ClickHouse, Inc.
“With ClickHouse Cloud, our developers can go from concept to delivery on a new analytical feature in days, instead of weeks. And our operations teams do not have to spend cycles tuning cluster performance for even the most demanding workloads,” says Varun Krishnani of Adevinta. “Decoupled storage and compute architecture and usage-based pricing ensures that we don’t have to over-provision infrastructure, and as a result, our business moves even faster to deliver value to our users at a reduced cost.”
"We use ClickHouse Cloud to monitor millions of real-time web performance data points, to ensure we’re getting faster all the time,” says Daunish Aboobaker, VP Engineering at Minted. ”The platform delivers fast and reliable data management, while also proving to be cost efficient and user-friendly."
ClickHouse Cloud is available immediately in Public Beta. Join the hundreds of development teams that have already been using ClickHouse Cloud throughout the company's private preview and early access programs by signing up for a free trial at www.clickhouse.com.
About ClickHouse
ClickHouse is the world's fastest and most resource efficient online analytical column-oriented database management system. Now offered as a secure and scalable serverless offering in the cloud, ClickHouse Cloud allows anyone to effortlessly take advantage of efficient real time analytical processing. Learn more at clickhouse.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005244/en/
Contact information
Tanya Bragin
VP, Product
press@clickhouse.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom